Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €11.76 EUR
Change Today +0.10 / 0.86%
Volume 1.9K
As of 9:50 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

vexim sa (ALVXM) Snapshot

Open
€11.52
Previous Close
€11.66
Day High
€11.77
Day Low
€11.50
52 Week High
03/2/15 - €13.13
52 Week Low
10/16/14 - €9.51
Market Cap
74.6M
Average Volume 10 Days
9.6K
EPS TTM
€-1.03
Shares Outstanding
6.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VEXIM SA (ALVXM)

Related News

No related news articles were found.

vexim sa (ALVXM) Related Businessweek News

No Related Businessweek News Found

vexim sa (ALVXM) Details

Vexim SA, a medical device company, designs and markets minimally invasive solutions for the treatment of traumatic spinal pathologies. The company markets the SpineJack, an implant capable of repairing a deformed or fractured vertebra and restoring the anatomy of the spinal column. It also offers vertebroplasty therapy products comprising cement injection kit; Cohesion, a biocompatible high viscosity bone cement for pathological fracture; and Interface, a bone composite for traumatic fracture. The company sells its products through its sales teams in France, Germany, Italy, Spain, Switzerland, and the United Kingdom, as well as through distributors in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama, Mexico, Brazil, Venezuela, Ecuador, and Peru. Vexim SA is headquartered in Balma, France.

50 Employees
Last Reported Date: 04/29/14

vexim sa (ALVXM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vexim sa (ALVXM) Key Developments

Vexim SA Reports Consolidated Sales Results for the First Quarter Ended March 31, 2015

Vexim SA reported consolidated sales results for the first quarter ended March 31, 2015. For the quarter, the company reported sales of EUR 2,720,000 against EUR 2,128,000 a year ago. This increase in sales was primarily driven by the continued penetration of SpineJack® technology across all geographic regions covered by VEXIM.

VEXIM Announces Consolidated Earnings Results for the Year Ended December 31, 2014

VEXIM announced consolidated earnings results for the year ended December 31, 2014. For the year, the company recorded annual sales of EUR 10.3 million compared to EUR 6.15 million a year ago. This increase is due to the continued adoption of the SpineJack® technology, with more than 8,000 implants sold in 2014. Operating loss wasEUR 6.104 million compared to EUR 6.899 million a year ago. Net loss was EUR 6.160 million compared to EUR 6.877 million a year ago.

VEXIM Obtains CE Approval to Market Masterflow TM1 Injection System in Europe

VEXIM announced the grant of the European CE approval of Masterflow TM1, a fully integrated system for mixing and injecting orthopedic cement for vertebral augmentations. The MasterflowTM Injection System for Vertebral Augmentation now affords a more intuitive process for accessing the vertebral body for cement delivery and is unique in its simplicity, accuracy and control of the injection of high-viscosity cement to treat vertebral compression fractures. MasterflowTM was introduced in the U.S. market at the beginning of the year. This patented system optimizes each stage of the injection process maximizing patients’ and surgeons’ safety, including: Complete control of the delivery of high viscosity cement with immediate halting of the flow, Complete optimization of the procedure, which enhances clinical performance, MasterflowTM complements the Company’s SpineJack technology by expanding its presence in the field of vertebroplasty, which currently represents approximately half of the minimally invasive procedures to treat vertebral compression.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALVXM:FP €11.76 EUR +0.10

ALVXM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Globus Medical Inc $24.79 USD +0.15
NuVasive Inc $43.99 USD +0.23
Stryker Corp $96.90 USD -0.28
Synthesis Energy Systems Inc $1.08 USD -0.07
Zimmer Holdings Inc $118.76 USD +0.19
View Industry Companies
 

Industry Analysis

ALVXM

Industry Average

Valuation ALVXM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VEXIM SA, please visit www.vexim.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.